Discussion associated to the approval of Zepbound proved one a part of a broader 14% enhance within the variety of mentions by HCPs regarding new pharmaceutical product launches and drug approvals compared to October’s statistics. November’s analysis additionally discovered that 166 extra particular person HCPs had been concerned in discussing therapy approvals than the earlier month.

On Nov. 16, the FDA permitted Pfizer and Astellas’ Xtandi (enzalutamide) for non-metastatic castration-sensitive prostate most cancers. This follows on from the European Medicines Agency’s approval of Xtandi for a similar indication in September. Quite a lot of HCPs expressed pleasure on the information, with some sharing an OncoAlert publication that reported on the approval. Chandler Park, MD, an oncologist and most cancers researcher, referred to as the therapy “practice changing,” whereas different HCPs congratulated their friends on the success of the EMBARK medical trial, which had been assessing the therapy.

Also on Nov. 16, the FDA introduced the approval of AstraZeneca’s Truqap (capivasertib with fulvestrant) for the therapy of hormone receptor-positive/HER2-negative metastatic breast most cancers. After its approval, Paolo Tarantino, MD, a analysis fellow on the Dana-Farber Cancer Institute, sparked dialog associated to a subanalysis of the CAPItello-291 trial, which was introduced on the San Antonio Breast Cancer Symposium. Overall, HCPs expressed help for its approval, notably in its capability as one other therapy choice for sufferers with breast most cancers.

The findings type a part of a wider examine by main digital insights consultancy Creation Healthcare, and are primarily based on the evaluation of two,313 English-language posts on X (previously Twitter) by 1,633 HCPs all through November, specializing in the approval and launch of latest merchandise.

Over the interval, the three most shared tales from HCPs discussing product launches included an Eli Lilly press launch on the approval of Zepbound for the therapy of weight problems and weight administration, a Cision PR Newswire article on the approval of Xtandi for the therapy of prostate most cancers, and an FDA press launch on the approval of Truqap for the therapy of hormone receptor-positive/HER2-negative metastatic breast most cancers.

References: 

• Chandler Park, MD, FACP (@CParkMD). Nov. 21, 2023. X (Twitter).
• Emad Shash (@emadshash). Nov. 17, 2023. X (Twitter).
• Erin D. Michos, MD (@ErinMichos). Nov. 8, 2023. X (Twitter).
• FDA approves capivasertib with fulvestrant for breast most cancers. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-fulvestrant-breast-cancer. Published Nov. 16, 2023. Accessed Dec. 20, 2023.
• FDA approves Lilly’s Zepbound (tirzepatide) for continual weight administration, a strong new choice for the therapy of weight problems or chubby with weight-related medical issues. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight. Published Nov. 8, 2023. Accessed Dec. 20, 2023.
• Jen Manne-Goehler (@IDDocJen). Nov. 9, 2023. X (Twitter).
• Komal Jhaveri (@jhaveri_komal). Nov. 16, 2023. X (Twitter).
• Neeraj Agarwal, MD, FASCO (@neerajaiims). Nov. 17, 2023. X (Twitter).
• OncoAlert (@OncoAlert). Nov. 23, 2023. X (Twitter).
• Paolo Tarantino (@PTarantinoMD). Nov. 30, 2023. X (Twitter).
• Payal Kohli, MD (@payalkohlimd). Nov. 16, 2023. X (Twitter).
• Pfizer and Astellas’ XTANDI permitted by U.S. FDA in earlier prostate most cancers therapy setting. https://www.prnewswire.com/news-releases/pfizer-and-astellas-xtandi-approved-by-us-fda-in-earlier-prostate-cancer-treatment-setting-301991574.html. Published Nov. 16, 2023. Accessed Dec. 20, 2023.

Published by: